FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2969857583> ?p ?o ?g. }

• W2969857583 endingPage "e030731" @default.
• W2969857583 startingPage "e030731" @default.
• W2969857583 abstract "Introduction Stereotactic body radiotherapy (SBRT) is a non-invasive alternative to surgery for the treatment of non-metastatic prostate cancer (PC). The objectives of the Novel Integration of N ew prostate radiation schedules with adJuvant Androgen deprivation (NINJA) clinical trial are to compare two emerging SBRT regimens for efficacy with technical substudies focussing on MRI only planning and the use of knowledge-based planning (KBP) to assess radiotherapy plan quality. Methods and analysis Eligible patients must have biopsy-proven unfavourable intermediate or favourable high-risk PC, have an Eastern Collaborative Oncology Group (ECOG) performance status 0-1 and provide written informed consent. All patients will receive 6 months in total of androgen deprivation therapy. Patients will be randomised to one of two SBRT regimens. The first will be 40 Gy in five fractions given on alternating days (SBRT monotherapy). The second will be 20 Gy in two fractions given 1 week apart followed 2 weeks later by 36 Gy in 12 fractions given five times per week (virtual high-dose rate boost (HDRB)). The primary efficacy outcome will be biochemical clinical control at 5 years. Secondary endpoints for the initial portion of NINJA look at the transition of centres towards MRI only planning and the impact of KBP on real-time (RT) plan assessment. The first 150 men will demonstrate accrual feasibility as well as addressing the KBP and MRI planning aims, prior to proceeding with total accrual to 472 patients as a phase III randomised controlled trial. Ethics and dissemination NINJA is a multicentre cooperative clinical trial comparing two SBRT regimens for men with PC. It builds on promising results from several single-armed studies, and explores radiation dose escalation in the Virtual HDRB arm. The initial component includes novel technical elements, and will form an important platform set for a definitive phase III study. Trial registration number ANZCTN 12615000223538." @default.
• W2969857583 created "2019-08-29" @default.
• W2969857583 creator A5004560596 @default.
• W2969857583 creator A5006770720 @default.
• W2969857583 creator A5012356605 @default.
• W2969857583 creator A5015992547 @default.
• W2969857583 creator A5024160417 @default.
• W2969857583 creator A5026020335 @default.
• W2969857583 creator A5026426772 @default.
• W2969857583 creator A5026470588 @default.
• W2969857583 creator A5031495990 @default.
• W2969857583 creator A5037268581 @default.
• W2969857583 creator A5044519122 @default.
• W2969857583 creator A5048110125 @default.
• W2969857583 creator A5049428169 @default.
• W2969857583 creator A5055591728 @default.
• W2969857583 creator A5061844500 @default.
• W2969857583 creator A5070465378 @default.
• W2969857583 creator A5074661336 @default.
• W2969857583 creator A5081872150 @default.
• W2969857583 creator A5082101408 @default.
• W2969857583 creator A5082669323 @default.
• W2969857583 creator A5083551834 @default.
• W2969857583 creator A5083630049 @default.
• W2969857583 creator A5083886265 @default.
• W2969857583 creator A5085425260 @default.
• W2969857583 date "2019-08-01" @default.
• W2969857583 modified "2023-10-17" @default.
• W2969857583 title "TROG 18.01 phase III randomised clinical trial of the Novel Integration of New prostate radiation schedules with adJuvant Androgen deprivation: NINJA study protocol" @default.
• W2969857583 cites W1822713087 @default.
• W2969857583 cites W1979641127 @default.
• W2969857583 cites W2004246843 @default.
• W2969857583 cites W2008090769 @default.
• W2969857583 cites W2014959613 @default.
• W2969857583 cites W2030378684 @default.
• W2969857583 cites W2078064304 @default.
• W2969857583 cites W2083321519 @default.
• W2969857583 cites W2084095675 @default.
• W2969857583 cites W2087295920 @default.
• W2969857583 cites W2094442174 @default.
• W2969857583 cites W2154412552 @default.
• W2969857583 cites W2155378784 @default.
• W2969857583 cites W2156516389 @default.
• W2969857583 cites W2161501889 @default.
• W2969857583 cites W2167080855 @default.
• W2969857583 cites W2296809578 @default.
• W2969857583 cites W2465092116 @default.
• W2969857583 cites W2470255787 @default.
• W2969857583 cites W2530107623 @default.
• W2969857583 cites W2553678345 @default.
• W2969857583 cites W2560303100 @default.
• W2969857583 cites W2569728867 @default.
• W2969857583 cites W2587309303 @default.
• W2969857583 cites W2590373595 @default.
• W2969857583 cites W2592315054 @default.
• W2969857583 cites W2592375521 @default.
• W2969857583 cites W2603384438 @default.
• W2969857583 cites W2626316238 @default.
• W2969857583 cites W2732019947 @default.
• W2969857583 cites W2742932486 @default.
• W2969857583 cites W2774168605 @default.
• W2969857583 cites W2783468264 @default.
• W2969857583 cites W2784003925 @default.
• W2969857583 cites W2807598871 @default.
• W2969857583 cites W2809576890 @default.
• W2969857583 cites W2897539375 @default.
• W2969857583 cites W2935113313 @default.
• W2969857583 cites W2939813550 @default.
• W2969857583 cites W4233380544 @default.
• W2969857583 doi "https://doi.org/10.1136/bmjopen-2019-030731" @default.
• W2969857583 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6707760" @default.
• W2969857583 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31434782" @default.
• W2969857583 hasPublicationYear "2019" @default.
• W2969857583 type Work @default.
• W2969857583 sameAs 2969857583 @default.
• W2969857583 citedByCount "15" @default.
• W2969857583 countsByYear W29698575832020 @default.
• W2969857583 countsByYear W29698575832021 @default.
• W2969857583 countsByYear W29698575832022 @default.
• W2969857583 countsByYear W29698575832023 @default.
• W2969857583 crossrefType "journal-article" @default.
• W2969857583 hasAuthorship W2969857583A5004560596 @default.
• W2969857583 hasAuthorship W2969857583A5006770720 @default.
• W2969857583 hasAuthorship W2969857583A5012356605 @default.
• W2969857583 hasAuthorship W2969857583A5015992547 @default.
• W2969857583 hasAuthorship W2969857583A5024160417 @default.
• W2969857583 hasAuthorship W2969857583A5026020335 @default.
• W2969857583 hasAuthorship W2969857583A5026426772 @default.
• W2969857583 hasAuthorship W2969857583A5026470588 @default.
• W2969857583 hasAuthorship W2969857583A5031495990 @default.
• W2969857583 hasAuthorship W2969857583A5037268581 @default.
• W2969857583 hasAuthorship W2969857583A5044519122 @default.
• W2969857583 hasAuthorship W2969857583A5048110125 @default.
• W2969857583 hasAuthorship W2969857583A5049428169 @default.
• W2969857583 hasAuthorship W2969857583A5055591728 @default.
• W2969857583 hasAuthorship W2969857583A5061844500 @default.
• W2969857583 hasAuthorship W2969857583A5070465378 @default.
• W2969857583 hasAuthorship W2969857583A5074661336 @default.

• next